Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses a few combinations that are being investigated for the treatment of patients with mantle cell lymphoma (MCL).
Investigators are currently looking at combinations with novel agents such as venetoclax (Venclexta), which Goy says is going to be very important in the field of MCL. In addition, CAR T-cell therapy can also play a role in the treatment of patients with relapsed/refractory disease, he says.
Goy says his institution is part of the integration of these novel therapies that have made such an in the relapsed/refractory setting and the next step is determining how they can be brought to the frontline.